Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Ewing Sarcoma Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Ewing Sarcoma Overview | 11 | 1 |
| Pipeline Products for Ewing Sarcoma Comparative Analysis | 12 | 1 |
| Ewing Sarcoma Therapeutics under Development by Companies | 13 | 2 |
| Ewing Sarcoma Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Ewing Sarcoma Pipeline Products Glance | 16 | 2 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Ewing Sarcoma Products under Development by Companies | 18 | 2 |
| Ewing Sarcoma Products under Investigation by Universities/Institutes | 20 | 1 |
| Ewing Sarcoma Companies Involved in Therapeutics Development | 21 | 20 |
| Astellas Pharma Inc. | 21 | 1 |
| Cebiotex, S.L. | 22 | 1 |
| Celgene Corporation | 23 | 1 |
| EntreChem, S.L. | 24 | 1 |
| Exelixis, Inc. | 25 | 1 |
| Gradalis Inc. | 26 | 1 |
| Kolltan Pharmaceuticals, Inc. | 27 | 1 |
| Merck &Co., Inc. | 28 | 1 |
| Merrimack Pharmaceuticals, Inc. | 29 | 1 |
| NanoSmart Pharmaceuticals, Inc. | 30 | 1 |
| Nanovalent Pharmaceuticals Inc. | 31 | 1 |
| NantKwest, Inc. | 32 | 1 |
| Novartis AG | 33 | 1 |
| Oncomatryx Biopharma, S.L. | 34 | 1 |
| Oncternal Therapeutics, Inc. | 35 | 1 |
| Pfizer Inc. | 36 | 1 |
| Pharma Mar, S.A. | 37 | 1 |
| Recombio S.L | 38 | 1 |
| Shionogi &Co., Ltd. | 39 | 1 |
| Tesaro, Inc. | 40 | 1 |
| Ewing Sarcoma Therapeutics Assessment | 41 | 11 |
| Assessment by Monotherapy Products | 41 | 1 |
| Assessment by Target | 42 | 3 |
| Assessment by Mechanism of Action | 45 | 3 |
| Assessment by Route of Administration | 48 | 2 |
| Assessment by Molecule Type | 50 | 2 |
| Drug Profiles | 52 | 147 |
| axitinib Drug Profile | 52 | 6 |
| cabozantinib s-malate Drug Profile | 58 | 18 |
| CEB-01 Drug Profile | 76 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 77 | 2 |
| Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology Drug Profile | 79 | 1 |
| celyvir Drug Profile | 80 | 1 |
| Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma Drug Profile | 81 | 1 |
| EC-8042 Drug Profile | 82 | 1 |
| EC-8105 Drug Profile | 83 | 1 |
| everolimus Drug Profile | 84 | 12 |
| gemogenovatucel-T Drug Profile | 96 | 4 |
| haNK Program Drug Profile | 100 | 1 |
| irinotecan hydrochloride Drug Profile | 101 | 11 |
| KITSG-3227 Drug Profile | 112 | 1 |
| KTN-0182A Drug Profile | 113 | 1 |
| linsitinib Drug Profile | 114 | 2 |
| lurbinectedin Drug Profile | 116 | 7 |
| Monoclonal Antibody Conjugate for Ewing Sarcoma Drug Profile | 123 | 1 |
| Monoclonal Antibody to Inhibit GD2 for Oncology Drug Profile | 124 | 1 |
| niraparib Drug Profile | 125 | 6 |
| NV-101 Drug Profile | 131 | 1 |
| OMTX-503 Drug Profile | 132 | 1 |
| OMTX-703 Drug Profile | 133 | 1 |
| ONC-206 Drug Profile | 134 | 1 |
| paclitaxel albumin bound Drug Profile | 135 | 8 |
| pazopanib hydrochloride Drug Profile | 143 | 7 |
| pembrolizumab Drug Profile | 150 | 37 |
| racotumomab Drug Profile | 187 | 2 |
| RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma Drug Profile | 189 | 1 |
| roneparstat Drug Profile | 190 | 1 |
| S-588410 Drug Profile | 191 | 2 |
| Small Molecules for Ewing Sarcoma Drug Profile | 193 | 1 |
| SP-2509 Drug Profile | 194 | 1 |
| SP-2528 Drug Profile | 195 | 1 |
| SP-2577 Drug Profile | 196 | 1 |
| TK-216 Drug Profile | 197 | 1 |
| Vimo-101 Drug Profile | 198 | 1 |
| Ewing Sarcoma Dormant Projects | 199 | 2 |
| Ewing Sarcoma Discontinued Products | 201 | 1 |
| Ewing Sarcoma Product Development Milestones | 202 | 7 |
| Featured News &Press Releases | 202 | 1 |
| Oct 24, 2016: Gradalis Announces the Appointment of Dr. Brian Daniels to the Newly Formed Scientific Advisory Board | 202 | 1 |
| Oct 17, 2016: Gradalis to Participate in 2nd Annual iC3 Life Science Summit Hosted By BioNorthTX | 202 | 1 |
| Aug 30, 2016: Oncternal Therapeutics Initiates Patient Dosing in Phase 1 Clinical Trial of TK216 in Ewing Sarcoma | 203 | 1 |
| Jul 13, 2016: TK216 Receives Orphan Drug Designation for the Treatment of Ewing Sarcoma, a Rare Pediatric Cancer | 203 | 1 |
| Jun 20, 2016: Oncternal Receives Fast Track Designation for TK216 in Relapsed or Refractory Ewing Sarcoma | 204 | 1 |
| Jul 30, 2015: NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer | 205 | 1 |
| Jun 04, 2015: Gradalis Announces Presentation of Data From a Pilot Study of Vigil Cancer Vaccine in Ewing s Sarcoma | 205 | 1 |
| Feb 11, 2015: NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing's Sarcoma | 206 | 1 |
| Nov 26, 2012: Possible New Treatment for a Childhood Cancer | 206 | 1 |
| Apr 16, 2012: EntreChem's Mithramycin Analog EC-8042 Shows Increased Potency And High Selectivity For Treatment Of Sarcoma | 207 | 1 |
| Apr 16, 2012: EntreChem's Mithramycin Shows Increased Potency And Higher Selectivity For Treatment Of Sarcoma | 208 | 1 |
| Appendix | 209 | 2 |
| Methodology | 209 | 1 |
| Coverage | 209 | 1 |
| Secondary Research | 209 | 1 |
| Primary Research | 209 | 1 |
| Expert Panel Validation | 209 | 1 |
| Contact Us | 209 | 1 |
| Disclaimer | 210 | 1 |